We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Read MoreHide Full Article
Key Takeaways
RXRX is advancing fibrosis, oncology, and neuroscience treatments via major pharma collaborations.
Deals with Bayer, Roche, Sanofi, and Merck offer multi-billion milestone and royalty opportunities.
BioHive-2 upgrade, Exscientia buyout, and tech alliances boost RXRX's AI capabilities and pipeline.
Recursion Pharmaceuticals (RXRX - Free Report) is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability. By partnering with major pharmaceutical companies, Recursion Pharmaceuticalsnot only expands its pipeline but also secures substantial non-dilutive funding to support its R&D activities.
Through its collaboration with Bayer, Recursion Pharmaceuticals is advancing treatments for fibrosis, with potential milestone payments totaling up to $1.5 billion and tiered royalties, reinforcing its revenue potential. Its agreement with Roche focuses on neuroscience and oncology, giving Roche the option to launch up to 40 programs, each of which could yield more than $300 million in milestones for RXRX, along with royalties. Partnerships with Sanofi and Merck further diversify Recursion Pharmaceuticals’ pipeline across oncology, immunology, and neuroinflammation, together offering billions in milestone opportunities and consistent royalty streams.
In addition to these pharma collaborations, Recursion Pharmaceuticals is investing heavily in AI infrastructure. Its alliance with NVIDIA led to the 2024 upgrade of its supercomputer to BioHive-2. The acquisition of Exscientia in late 2024 added over 20 programs to Recursion Pharmaceuticals’ portfolio and increased its milestone opportunity to more than $20 billion, strengthening its financial foundation.
Further collaborations with technology leaders like Google Cloud, Helix, and Faro Health enhance RXRX’s AI capabilities, accelerating drug discovery and development. These strategic partnerships not only provide immediate financial support but also amplify Recursion Pharmaceuticals’ ability to scale its platform, pursue innovative therapies, and forge new alliances, positioning the company for sustained, long-term success in the evolving biotech landscape.
RXRX Faces Competitive Pressure in the TechBio Industry
In the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) are emerging as strong competitors to Recursion Pharmaceuticals, who also leverage AI-driven platforms to enter into strategic collaboration agreements and develop novel therapies. RLAY is on track to advance its lead investigational candidate, RLY-2608, into a phase III study for metastatic breast cancer. An early-stage study evaluating the candidate for a second indication, vascular malformations, is also currently underway.
Meanwhile, SDGR’s lead asset SGR-1505 is currently being evaluated in an early-stage study for B-cell malignancies. Schrödinger is also evaluating two other candidates, SGR-2921 and SGR-3515, in separate phase I studies for leukemia and solid tumors. Both Relay Therapeutics and Schrödinger are steadily building robust pipelines through cutting-edge approaches.
RXRX’sStock Price, Valuation & Estimate Movements
Year to date, RXRX shares have plunged 22.8% against the industry’s 0.1% growth. Recursion Pharmaceuticals has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
RXRX Stock Underperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Recursion Pharmaceuticals is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.27, which is less than 3.14 for the industry. The stock is trading significantly below its five-year mean of 3.56.
RXRX Stock Valuation
Image Source: Zacks Investment Research
Loss estimates for 2025 have remained constant at $1.34 per share over the past 60 days. During the same time frame, RXRX’s 2026 loss per share estimates have narrowed from $1.17 to $1.08.
Image: Bigstock
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Key Takeaways
Recursion Pharmaceuticals (RXRX - Free Report) is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability. By partnering with major pharmaceutical companies, Recursion Pharmaceuticals not only expands its pipeline but also secures substantial non-dilutive funding to support its R&D activities.
Through its collaboration with Bayer, Recursion Pharmaceuticals is advancing treatments for fibrosis, with potential milestone payments totaling up to $1.5 billion and tiered royalties, reinforcing its revenue potential. Its agreement with Roche focuses on neuroscience and oncology, giving Roche the option to launch up to 40 programs, each of which could yield more than $300 million in milestones for RXRX, along with royalties. Partnerships with Sanofi and Merck further diversify Recursion Pharmaceuticals’ pipeline across oncology, immunology, and neuroinflammation, together offering billions in milestone opportunities and consistent royalty streams.
In addition to these pharma collaborations, Recursion Pharmaceuticals is investing heavily in AI infrastructure. Its alliance with NVIDIA led to the 2024 upgrade of its supercomputer to BioHive-2. The acquisition of Exscientia in late 2024 added over 20 programs to Recursion Pharmaceuticals’ portfolio and increased its milestone opportunity to more than $20 billion, strengthening its financial foundation.
Further collaborations with technology leaders like Google Cloud, Helix, and Faro Health enhance RXRX’s AI capabilities, accelerating drug discovery and development. These strategic partnerships not only provide immediate financial support but also amplify Recursion Pharmaceuticals’ ability to scale its platform, pursue innovative therapies, and forge new alliances, positioning the company for sustained, long-term success in the evolving biotech landscape.
RXRX Faces Competitive Pressure in the TechBio Industry
In the TechBio space, Relay Therapeutics (RLAY - Free Report) and Schrödinger (SDGR - Free Report) are emerging as strong competitors to Recursion Pharmaceuticals, who also leverage AI-driven platforms to enter into strategic collaboration agreements and develop novel therapies. RLAY is on track to advance its lead investigational candidate, RLY-2608, into a phase III study for metastatic breast cancer. An early-stage study evaluating the candidate for a second indication, vascular malformations, is also currently underway.
Meanwhile, SDGR’s lead asset SGR-1505 is currently being evaluated in an early-stage study for B-cell malignancies. Schrödinger is also evaluating two other candidates, SGR-2921 and SGR-3515, in separate phase I studies for leukemia and solid tumors. Both Relay Therapeutics and Schrödinger are steadily building robust pipelines through cutting-edge approaches.
RXRX’sStock Price, Valuation & Estimate Movements
Year to date, RXRX shares have plunged 22.8% against the industry’s 0.1% growth. Recursion Pharmaceuticals has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
RXRX Stock Underperforms the Industry, Sector & the S&P 500
Recursion Pharmaceuticals is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.27, which is less than 3.14 for the industry. The stock is trading significantly below its five-year mean of 3.56.
RXRX Stock Valuation
Loss estimates for 2025 have remained constant at $1.34 per share over the past 60 days. During the same time frame, RXRX’s 2026 loss per share estimates have narrowed from $1.17 to $1.08.
RXRX Estimate Movement
Recursion Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.